Xenetic Biosciences Croissance future

Future contrôle des critères 2/6

Les bénéfices de Xenetic Biosciences devraient diminuer de 34.4% par an tandis que son chiffre d'affaires annuel devrait croître de 35.9% par an. Le BPA devrait croître de en hausse de 25.8% par an.

Informations clés

-34.4%

Taux de croissance des bénéfices

25.8%

Taux de croissance du BPA

Biotechs croissance des bénéfices	28.4%
Taux de croissance des recettes	35.9%
Rendement futur des capitaux propres	n/a
Couverture par les analystes	Low
Dernière mise à jour	21 Nov 2024

Mises à jour récentes de la croissance future

Recent updates

Most Shareholders Will Probably Find That The Compensation For Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Is Reasonable

Dec 15

Why We Think Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Compensation Is Not Excessive At All

Dec 01

Xenetic Biosciences reports Q2 results

Aug 12

Xenetic Biosciences, VolitionRx collaborate to develop cell therapies to treat cancer

Aug 02

Xenetic inks clinical manufacturing contract with Catalent

Jul 07

Xenetic Biosciences reports Q3 results

Nov 13

Prévisions de croissance des bénéfices et des revenus

NasdaqCM:XBIO - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	2	-15	N/A	N/A	1
12/31/2025	2	-9	N/A	N/A	1
12/31/2024	2	-6	N/A	N/A	1
9/30/2024	3	-4	-3	-3	N/A
6/30/2024	3	-5	-3	-3	N/A
3/31/2024	2	-4	-4	-4	N/A
12/31/2023	3	-4	-4	-4	N/A
9/30/2023	2	-4	-4	-4	N/A
6/30/2023	2	-4	-4	-4	N/A
3/31/2023	2	-6	-4	-4	N/A
12/31/2022	2	-7	-5	-5	N/A
9/30/2022	2	-7	-6	-5	N/A
6/30/2022	1	-7	-6	-5	N/A
3/31/2022	1	-6	-5	-5	N/A
12/31/2021	1	-6	-5	-5	N/A
9/30/2021	1	-5	-4	-4	N/A
6/30/2021	1	-11	-4	-4	N/A
3/31/2021	1	-11	-5	-5	N/A
12/31/2020	0	-11	-4	-4	N/A
9/30/2020	0	-11	-5	-5	N/A
6/30/2020	0	-14	-6	-6	N/A
3/31/2020	0	-14	-6	-6	N/A
12/31/2019	0	-18	-6	-6	N/A
9/30/2019	N/A	-19	-6	-6	N/A
6/30/2019	N/A	-10	-5	-5	N/A
3/31/2019	N/A	-11	-6	-6	N/A
12/31/2018	N/A	-7	-6	-6	N/A
9/30/2018	8	-1	-1	-1	N/A
6/30/2018	8	-2	N/A	-1	N/A
3/31/2018	8	-3	N/A	0	N/A
12/31/2017	8	-4	N/A	1	N/A
9/30/2017	3	-12	N/A	-8	N/A
6/30/2017	3	-13	N/A	-7	N/A
3/31/2017	3	-58	N/A	-7	N/A
12/31/2016	3	-58	N/A	-9	N/A
9/30/2016	N/A	-57	N/A	-5	N/A
6/30/2016	N/A	-60	N/A	-6	N/A
3/31/2016	N/A	-14	N/A	-5	N/A
12/31/2015	N/A	-13	N/A	-5	N/A
9/30/2015	N/A	-13	N/A	-7	N/A
6/30/2015	N/A	-11	N/A	-8	N/A
3/31/2015	N/A	-13	N/A	-11	N/A
12/31/2014	N/A	-14	N/A	-13	N/A
9/30/2014	N/A	-14	N/A	-12	N/A
6/30/2014	N/A	-13	N/A	-12	N/A
3/31/2014	1	-11	N/A	-9	N/A
12/31/2013	1	-9	N/A	-6	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: XBIO devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: XBIO devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: XBIO devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de XBIO ( 35.9% par an) devrait croître plus rapidement que le marché US ( 9% par an).

Croissance élevée des revenus: Le chiffre d'affaires de XBIO ( 35.9% par an) devrait croître plus rapidement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de XBIO devrait être élevé dans 3 ans

Xenetic Biosciences Croissance future

Future contrôle des critères 2/6

Informations clés

Mises à jour récentes de la croissance future

Price target increased to US$4.00

Consensus forecasts updated

Consensus EPS estimates increase to -US$0.55

Price target increased to US$5.00

Recent updates

Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting Potential of Co-Administration of DNase I with CAR T Cells in Murine Model of Melanoma Lung Metastasis

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Xenetic Biosciences, Inc. Announces the Presentation of Positive Preclinical Data

Xenetic Biosciences, Inc., Annual General Meeting, Dec 11, 2024

Second quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat

Xenetic Biosciences, Inc. Announces the Appointment of James Parslow as Interim Chief Executive Officer

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

CLS Therapeutics Discloses its Views on Xenetic Biosciences

Xenetic Biosciences, Inc. Enters into Research Agreement with the University of Virginia for the Advancement of Its DNase-Based Oncology Platform

Xenetic Biosciences, Inc., Annual General Meeting, Dec 06, 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Most Shareholders Will Probably Find That The Compensation For Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Is Reasonable

Xenetic Biosciences, Inc., Annual General Meeting, Dec 21, 2022

Xenetic Biosciences Receives a Non-Compliance Letter from Nasdaq

Why We Think Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Compensation Is Not Excessive At All

Xenetic Biosciences, Inc. Announces the Appointment of Jonathan Spicer to its Scientific Advisory Board

Price target increased to US$4.00

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Xenetic Biosciences, Inc., Annual General Meeting, Dec 07, 2022

Xenetic Biosciences, Inc. announced that it expects to receive $0.488835 million in funding from CLS Therapeutics, Inc.

Xenetic Biosciences, Inc. Appoints Allan Tsung, to Its Scientific Advisory Board

Consensus forecasts updated

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Xenetic Biosciences reports Q2 results

Xenetic Biosciences, VolitionRx collaborate to develop cell therapies to treat cancer

Xenetic inks clinical manufacturing contract with Catalent

Xenetic Biosciences Receives Written Notification from the Listing Qualifications Department of the Nasdaq

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Xenetic Biosciences, Inc. announced that it has received $0.86625 million in funding

High number of new directors

Third quarter 2021 earnings released: US$0.13 loss per share (vs US$1.20 loss in 3Q 2020)

Consensus EPS estimates increase to -US$0.55

Second quarter 2021 earnings released: US$0.13 loss per share (vs US$0.15 loss in 2Q 2020)

Price target increased to US$5.00

Xenetic Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $6.000001 million.

Xenetic Biosciences reports Q3 results

Xenetic Biosciences Receives Notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC

Prévisions de croissance des bénéfices et des revenus

Prévisions de croissance des analystes

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

Découvrir les entreprises en croissance